Rankings
▼
Calendar
ABCL
AbCellera Biologics Inc.
$1B
Q2 2019 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$2M
Gross Profit
$468,009
18.9% margin
Operating Income
-$712,714
-28.7% margin
Net Income
-$302,883
-12.2% margin
EPS (Diluted)
$-0.00
QoQ Revenue Growth
-0.0%
Cash Flow
Operating Cash Flow
$2M
Free Cash Flow
-$156,478
Stock-Based Comp.
$158,033
← FY 2019
All Quarters
Q3 2019 →
ABCL Q2 2019 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena
